- Amdocs’ 2Q Adjusted EPS (Earnings Per Share) didn’t meet expectations, standing at $1.56 as compared to the estimated $1.57.
- The Adjusted EPS of $1.56 shows growth from the previous year’s $1.47.
- Amdocs reported a revenue of $1.25 billion, matching the estimates.
- The revenue has seen a positive year over year growth of +1.8%.
- Among the analyzed ratings, Amdocs has received 5 buys, 2 holds and notably, 0 sells.
A look at Amdocs Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using the Smartkarma Smart Scores have provided an overall positive outlook for Amdocs Ltd, a company that specializes in offering product-driven information system solutions to telecommunications giants globally. Amdocs scores a consistent 3 out of 5 across various key factors including Value, Dividend, Growth, Resilience, and Momentum. This indicates a balanced standing for the company in terms of its financial health, growth potential, and market performance.
Amdocs Limited, a provider of integrated customer care and billing systems for telecommunications operators and service providers, seems to demonstrate a stable and promising future according to the Smart Scores. With all factors falling across the middle range, Amdocs appears to have a steady foundation for potential growth and resilience in the dynamic telecommunications industry both in the United States and internationally.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
